A surface active layer consisting mainly of phospholipids lines the human conducting airways. Dysfunction of this layer could play a role in the pathogenesis of chronic obstructive airway diseases like asthma and chronic bronchitis. Replacement therapy with exogenous surfactants is being considered in such conditions. The relationship between surfactants and mucus viscosity would be important for such an application. Respiratory mucus is composed of high molecular weight glycoprotein molecules which form temporary cross-links and entanglements to form a gel-like material. The present paper studies the interaction of three therapeutic surfactants -Exosurf, ALEC and Survanta; the main phospholipids of lung surfactant (1,2-dipalmitoyl phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylglycerol (PG)) as well as their binary mixtures (PCPE and PCPG) in a PC:(PE or PG) ratio of 2:3; on the viscosity of mucus gel simulants (MGS -a polymeric gel consisting mainly of gum tragacanth and simulating respiratory mucus). The surfactants were studied with respect to their ability to alter MGS viscosity at shear rates ranging from 0.1498 to 51.2 s −1 in a concentric cylinder viscometer at 37 • C. The change in viscosity of the MGS on incubation with surfactant versus shear rate was found be non-Newtonian and to follow a power law model (coefficient of regression R 2 ≥ 0.9). The shear rates experienced by a surfactant mixture, while passing through the tracheobronchial tree, were then calculated by modelling the tracheobronchial tree as cylindrical branching tubes. The equation governing the flow of a power law fluid through a cylindrical pipe was used to determine the shear experienced by a surfactant infusion as it passes through various mucus lined branches of the tracheobronchial tree. The surfactants were then compared based on their ability to alter MGS viscosity at shear rates corresponding to that of large, medium and small bronchi, as calculated by the study.
Introduction
Lung surfactant, a complex mixture consisting mainly of surface active phospholipids and surfactant specific proteins, is known to stabilise and prevent alveoli from collapse during expiration [1, 2] by reduction of surface tension at the alveolar air-liquid interface of the lungs. Hence, surfactant replacement therapy has become the standard treatment of neonatal respiratory distress syndrome (RDS), a disease due to deficiency of lung surfactant. However, apart from the alveoli, surfactant also lines the narrow conducting airways of the tracheobronchial tree [3] . Functionally this surface active layer in the airways is responsible for maintenance of patency of airways [4] [5] [6] [7] . Thus, there is potential for a beneficial effect of surfactant therapy in obstructive airway diseases like asthma and chronic bronchitis.
Phospholipids are the major component of lung surfactant of which the majority is dipalmitoyl phosphatidylcholine. The airway surface active lining also contains phospholipids, the relative composition of which can alter the clearance properties of mucus [8, 9] . These lipids may exert their beneficial effects on airways by their surface activity [10] , by changing the adhesiveness of mucus to the airway epithelium [11] or by changing the mucus viscoelastic properties [12] . Respiratory mucus is composed of high molecular weight glycoprotein molecules which form temporary cross-links and entanglements to form a gel-like material [13] .
Though the role of surfactants in lowering surface tension is well documented [14] [15] [16] , very few studies have considered the effect of surfactants on rheology of respiratory mucus. Rubin et al. [17] have described the efficacy of Exosurf (a therapeutic non-protein surfactant) in decreasing the viscoelasticity of mucus in RDS. De Sanctis et al. [18] have studied the effect of Curosurf (a natural surfactant from minced pig lungs) on mucus viscosity and mucociliary clearance in dogs suffering from RDS. The tracheal mucus velocity was found to increase significantly but no changes were observed in viscoelastic parameters of mucus. Hence, the role of surfactants in alteration of viscosity of respiratory mucus is not well established.
Keeping in mind the similarity of respiratory mucus to a polymeric gel [13, 19, 20] and the presence of phospholipids in the surfactant lining the airways, the present study was proposed to evaluate the effect of surfactants on mucus viscosity at physiologically relevant shear rates. The effects of phospholipid mixtures on the viscosity of polymeric gums are described in a simulation of the effects of artificial replacements of bronchial surfactant on the viscosity of respiratory mucus. The study compares the effect of three commercially available therapeutic surfactants -ALEC, Exosurf and Survanta on the viscosity of mucus gel simulants (MGS). The effect of the three main phospholipids of pulmonary surfactant -namely 1,2-dipalmitoyl phosphatidylcholine (PC, usually abbreviated as DPPC), phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) on mucus gel rheology is also studied. The combined effect of binary mixtures of these phospholipids, in the PC:(PE or PG) ratio of 2:3, is also evaluated. This ratio was chosen due to the finding of Holm et al. [21] that phospholipid mixtures containing 40% DPPC performed better than phospholipid mixtures containing a higher percent of DPPC. A model is suggested which best fits the experimental data of the change of MGS viscosity, with shear rate, on surfactant addition. This is then used to estimate, in vitro, the shear rates experienced by the surfactant mucus gel mixture, through the various generations of the tracheobronchial tree. Finally, the surfactants are compared by their ability to alter MGS viscosity at shear rates corresponding to various branches of the tracheobronchial tree.
Materials and methods

Chemicals
PE, PC, and PG were purchased as >99% purity from the Sigma Chemical Company, St. Louis, MO. Exosurf Neonatal, Survanta and ALEC were obtained as kind gifts from Burroughs Wellcome Co., Research Triangle, NC; Ross Laboratories, Columbus, OH and Britannia Pharmaceuticals, Surrey, UK, respectively. Other chemicals used in the experiments were HPLC grade chloroform, and sodium tetrahydroborate (Qualigens Fine Chemicals, Glaxo, India). Gum tragacanth was purchased from Loba Chemicals, India as 99% purity. Sterile Ringer's lactate was obtained from Alberts David, India. Sterile distilled water and sterile normal saline were used, as supplied, for reconstitution of Exosurf and ALEC (artificial lung expanding compound). Survanta is a semisynthetic surfactant consisting of an extract from homogenised whole cow lungs to which PC is added. It contains the phospholipids of lung surfactant as well as the surfactant specific proteins. ALEC is a synthetic preparation containing 70% PC and 30% unsaturated phosphatidylglycerol. Exosurf is a synthetic preparation containing PC, the major phospholipid constituent of natural surfactant, hexadecanol -a 16-carbon alcohol which facilitates re-spreading of PC across an air-fluid interface, tyloxapol; which facilitates reconstitution of the lyophilised powder and sodium chloride to confer an appropriate osmolality.
MGS preparation
MGS was prepared in accordance with the procedures followed by Agarwal et al. [22] and King et al. [23] with a slight modification. Gum tragacanth was used instead of locust bean gum and guar gum. Gum tragacanth contains Ca 2+ , Mg 2+ and K + salts of tragacanthic acid, d-xylose, l-fucose, galacturonic acid, galactose and rhamnose. It was preferred over locust bean gum and guar gum due to the presence of fucose which simulates the respiratory fucomucins. Briefly, Ringer's lactate was added at 37 • C drop-wise with continuous stirring to 100 mg gum tragacanth powder to form a homogenous gel. Sodium tetrahydroborate was added for cross-linking to a final concentration of 0.01 M and the MGS was standardised to a viscosity of 20.5 ± 1 cP at a shear rate of 0.512 s −1 , and 14.1 ± 0.7 cP at 51.2 s −1 . The MGS was found to follow a power law (R 2 of 0.85) with the equation v = 19.397 s −0.082 , where v is the viscosity and s is the corresponding shear rate.
Rheology experiment
An amount of 20 l of phospholipid solution (either single or mixed) in chloroform (1 mg/ml) was added and mixed with 2 ml of MGS and incubated for half an hour at 37 • C. A control with the MGS and 20 l of chloroform was also incubated at the same temperature for the same time. In case of the therapeutic surfactants, 20 l of the surfactant, in the form recommended by the manufacturer's guidelines, was added to the MGS. Thus, in the case of Survanta, 20 l of the suspension was added to the MGS with equal volume of Ringer's lactate added to the control. In the case of Exosurf and ALEC, 20 l each of the reconstituted surfactant was added to the MGS. Equal volumes of sterile saline and sterile water were added to the controls for ALEC and Exosurf, respectively.
Viscosity of all samples were tested by application of steady state shear rates ranging from 0.1498 to 51.2 s −1 in a concentric cylinder viscometer (Contraves LS 30, Switzerland). Briefly, the sample was poured in the cup of the viscometer and its temperature allowed to equilibrate at 37 • C with the help of a surrounding constant temperature water bath. The bob was gently lowered into the cup taking precautions to adjust its position exactly in the centre without touching any sides of the cup. A range of increasing shear rates were then applied and the corresponding torques recorded. The viscosity was calculated by multiplying the torque obtained by certain fixed pre-calculated factors specified for each shear rate [24] .
The viscosity of the MGS after incubation with the surfactant was divided by the viscosity of the MGS after incubation with an equal volume of control solvent for the same time period. In this way, the ratio of change in MGS viscosity due to addition of surfactant was determined. The ratio of change in MGS viscosity was then plotted versus shear rate. The equation for the viscosity changes was determined by curve fitting and the coefficients obtained from the equations were used for determination of the shear rates experienced by the surfactant mucus gel mixture through the tracheobronchial tree, as described in the following section.
Results
The ratio of change in mucus gel viscosity due to surfactant addition was plotted against shear rate. The fitted curves for ratio of change in mucus viscosity with addition of surfactant versus shear rate are shown in Fig. 1 . The power law model (Eq. (1)) was found to give a very good fit (with coefficient of regression R 2 ≥ 0.9) for the trend of change in MGS viscosity with surfactant using the following equation:
where τ is the torque generated, proportional to the viscosity, and du/dr is the velocity gradient or shear rate.
Shear rates through the tracheobronchial tree
To determine the shear experienced by an intratracheal infusion of surfactant as it passes through the various generations of the mucus-lined tracheobronchial tree, the equation governing the laminar flow of a power law fluid in a circular pipe (Eq. (2)) was considered [25] :
where Q is the flow rate, n the power as obtained in the power law equation, G the negative pressure gradient and k is the coefficient of the power law equation. The pressure gradient is also given by 2τ /r [25] , where r is the radius of the airway branch being considered. On substitution and simplification of Eq. (2) we get the following equation:
The dimensions of the generations of airways were considered as described by Horsfield [26] . Q for the first generation was taken as 1.2 ml over 17.6 s -the rate of infusion of ALEC in a clinical study conducted by Ahluwalia and Morley [27] . Subsequent Q for each generation of branching was taken as Q n = Q n−1 /(no. of branches), where Q n is the flow of the present (nth) generation and Q n−1 the flow in the previous generation. The values of k and n obtained from the power law equation for PC were substituted in Eq. (3) as PC is the main functional constituent of most surfactants. The corresponding shear rates at each generation are summarised in Fig. 2 . Hence, it was seen that the average shear rate experienced in large bronchi of diameters 7-11.1 mm was 0.9079 s −1 , that in medium bronchi with diameters 4.3-7 mm was 0.7817 s −1 and that in small sized airways of diameter 2.8-3.5 mm was 0.2494 s −1 .
Viscosity at physiologic shear rates: Table 1 shows the ratio of change in MGS viscosity when comparing all the surfactants at shear rates of physiologic relevance. On comparing the change in MGS viscosity due to surfactants at these shear rates of physiologic relevance it was observed that in all three sizes of airways, namely large, medium and small bronchi, Exosurf and Survanta were equivalent in efficacy and caused the lowest change in mucus gel viscosity. The binary mixtures of PCPE and PCPG were significantly better than PC, with lower ratios of change in MGS viscosity, at all the shear rates of physiologic relevance.
Discussion
Though the model of the tracheobronchial tree as cylindrical tubes and the surfactant-mucus interaction as a power law fluid is a simplification, the present study helps to evaluate the rheological aspects of surfactants under physiologically relevant conditions of shear which have so far not been accounted for. Survanta and Exosurf were found to be superior to all other surfactants tested at the shear rates of physiological relevance. Crawford and Young [28] have observed appreciable amelioration of bronchoconstriction, assessed by lung function tests, in asthmatics after administration of Exosurf. The superior performance of Exosurf with regard to alteration of MGS viscosity could explain the effectiveness of Exosurf in clinical trials of asthmatic patients.
The use of PE or PG alone caused very high ratios of change in MGS viscosity. However, when combined with PC in the ratio of 2:3, both PCPE and PCPG caused significantly lower ratios of change in MGS viscosity (62.41% decrease in ratio due to PCPE when compared with PE, 40.77% decrease in ratio due to PCPG when compared with PG). In fact, the combination with PE or PG even slightly decreased the ratio obtained with PC alone (9% decrease in ratio due to PCPG when compared to PC).
Interestingly though, ALEC a mixture of PC:PG in the ratio 7:3 had the highest ratio of change in MGS viscosity. A lower concentration of PC in a binary mixture of phospholipids (as in PCPG) was beneficial from a rheological viewpoint (with lower ratios of change in mucus viscosity; a 50.11% decrease in the ratio of change in MGS viscosity at a shear rate of 0.91 s −1 , a 50.88% decrease at a shear rate of 0.78 s −1 and a decrease of 55.4% at a shear rate of 0.25 s −1 ) compared with binary mixtures of phospholipids with higher PC concentrations, e.g. ALEC. Low concentration PC in phospholipid mixtures have already been shown beneficial from a surface chemistry viewpoint by Holm et al. [21] . Their study concluded that surfactants with low PC in phospholipid mixtures would serve as good candidates for exogenous surfactants as surfactants containing 40% PC gave the most favourable response in surface pressure-area isotherms as compared to higher concentration mixtures. The superiority of low PC content in binary mixtures of phospholipids surfactants has been confirmed with respect to rheological properties, in this study, i.e. a mixture containing 70% PC and 30% PG (ALEC) performed worse than a mixture containing 40% PC and 60% PG (PCPG). However, this performance related to low amounts of PC was found to hold true only relative to the amount of other phospholipid. in the mixture. This is seen by the superior performance of Exosurf which contains 85% PC and 9% hexadecanol and 6% tyloxapol. Survanta and Exosurf were found to be far superior to all other surfactants tested at the shear rates of physiological relevance. They were found to be equivalent with respect to alteration of mucus viscosity in large, medium and small sized bronchi. This was probably due to the presence of surfactant specific proteins in Survanta and the presence of hexadecanol in Exosurf which improved the rheological effects of the phospholipids alone. It is to be noted that none of the surfactants decreased MGS viscosity and the lowest ratio of change in MGS viscosity seen was that of 1.42 ± 0.07 in large bronchi obtained by Exosurf. When using a surfactant for diseases like asthma and chronic bronchitis, the shear thinning effect and the effect on mucus viscosity at relevant shear rates is very important. Among the surfactants and phospholipids tested, Exosurf and Survanta should have a beneficial effect in these conditions due to their positive effects on MGS rheology. However, this is a relative assessment and in absolute terms, some other surfactant would be required which would be able to reduce the mucus viscosity (a ratio of change in MGS viscosity <1) at relevant shear rates. Further, the limitations of the present study should be kept in mind -the use of a simulant instead of actual mucus samples and the need for animal studies for determination of airway clearance and confirmation of the in vitro results. Clearly, further research into the interactions of surfactants on mucus properties is required to determine suitability of surfactants for chronic obstructive airway diseases.
Conclusions
To summarise, the present study modelled the tracheobronchial tree as cylindrical tubes and the surfactant-mucus interaction as a power law fluid. On surfactant addition, the change in viscosity of a polymeric mucus gel simulant versus shear rate was found be non-Newtonian and to follow a power law model. Survanta and Exosurf (two commercial surfactants) were found to be superior to all other surfactants tested at the shear rates of physiological relevance. When using a surfactant for diseases like asthma and chronic bronchitis, the shear thinning effect and the effect on mucus viscosity at relevant shear rates is very important. Among the surfactants and phospholipids tested, Exosurf and Survanta should have a beneficial effect in these conditions due to their positive effects on mucus gel simulant rheology.
